Clinical Trial

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-11-29; most recent amendment 2026-05-28.
Status change: Recruiting → Active, Not Recruiting 2025-11-03
Trial Details
NCT Number NCT06161584
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Geographic Atrophy
Enrollment 300 participants
Start Date 2023-09-28
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-01